NCT07185997 2026-02-10Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.Phase 3 Recruiting480 enrolled
NCT04614103 2025-11-12Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerIovance Biotherapeutics, Inc.Phase 2 Recruiting170 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT05361174 2024-12-05A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerIovance Biotherapeutics, Inc.Phase 1/2 Recruiting53 enrolled